drugset / Trial / NCT00006340

Ganciclovir Plus Arginine Butyrate in Treating Patients With Cancer or Lymphoproliferative Disorders Associated With the Epstein Barr Virus

NCT00006340

Phase 1 Completed Boston Medical Center
Treatment

Summary

RATIONALE: The Epstein Barr virus can cause cancer and lymphoproliferative disorders. Ganciclovir is an antiviral drug that acts against the Epstein Barr virus. Arginine butyrate may make virus cells more sensitive to ganciclovir. Combining ganciclovir and arginine butyrate may kill more Epstein Barr virus cells and tumor cells. PURPOSE: Phase I trial to study the effectiveness of arginine butyrate plus ganciclovir in treating patients who have cancer or lymphoproliferative disorders that are associated with the Epstein Barr virus.

Timeline

Start
1994-12
Primary completion
2000-07
Completion
2000-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Arginine Butyrate Small molecule 1000 mg/kg
Subject Ganciclovir Small molecule